donepezil has been researched along with Dementia Praecox in 37 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adjunctive treatment with donepezil improves cognition in patients with schizophrenia who are stabilized on atypical antipsychotics." | 9.14 | Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. ( Chung, YC; Kim, KW; Lee, CR; Park, TW; Yang, KH, 2009) |
| "The article mentions the conclusions of most evidential works investigating donepezil in the treatment of cognitive deficit in schizophrenia." | 9.12 | Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study. ( Kadlecová, E; Lenderová, Z; Pérez, M; Pytela, O; Tůma, I; Zemanová, M, 2006) |
| "Donepezil does not seem to improve negative signs and cognitive impairment in elderly patients with chronic schizophrenia." | 9.12 | Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. ( Barak, Y; Mazeh, D; Mirecki, I; Paleacu, D; Zemishlani, H, 2006) |
| "Donepezil, 5 mg/d for 6 wk then 10 mg/d for 6 wk, and placebo daily for 12 wk in a double-blind cross-over paradigm, was added to the therapeutic regimen of 13 patients with schizophrenia or schizoaffective disorders, clinically stable on atypical antipsychotic medications." | 9.12 | Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2006) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 9.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen." | 9.12 | Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2007) |
| "Similar to other studies using acetylcholinesterase inhibitors in more heterogeneous and symptomatic groups of patients with schizophrenia, donepezil does not appear to enhance cognitive abilities." | 9.12 | No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. ( Bilker, W; Gur, RC; Gur, RE; Kohler, CG; Kujawski, E; Martin, EA, 2007) |
| "Sixteen male patients with schizophrenia, who were receiving stable, physician-optimized risperidone (1-4 mg twice daily), and 15 healthy age- and weight-matched male controls, received donepezil HCl 5 mg daily for 7 days." | 9.11 | Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ( Cullen, EI; Khan, A; Kumar, D; Perdomo, CA; Pratt, RD; Preskorn, SH; Reyes, JF, 2004) |
| "Our aim was to examine if donepezil administered to stable, medicated outpatients with schizophrenia improves cognition and psychopathology." | 9.11 | Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. ( Cather, C; Deckersbach, T; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Herz, L, 2005) |
| "A pilot study was conducted to examine if donepezil could enhance cognitive function in patients with schizophrenia." | 9.10 | An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. ( Buchanan, RW; Gold, J; Summerfelt, A; Tek, C, 2003) |
| "The results of several clinical trials utilizing donepezil as an adjunct to second-generation antipsychotic drugs targeting cognitive deficits in schizophrenia subjects have been disappointing and would not lead clinicians to consider this as a potential treatment option." | 8.89 | Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia. ( Henderson, DC; Thakurathi, N; Vincenzi, B, 2013) |
| "Donepezil is the first-line of treatment for Alzheimer's disease (AD), which improves cognitive impairment effectively, but whether it has an impact on cognitive impairment in schizophrenia remains unknown." | 7.88 | The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia. ( Chen, T; He, L; Jia, XF; Li, YX; Ye, ZH, 2018) |
| "To assess the clinical and cognitive effects of adding donepezil, a reversible acetylcholinesterase inhibitor, to the risperidone treatment of a high functioning stable out-patient with schizophrenia." | 7.71 | Donepezil in schizophrenia--is it helpful? An experimental design case study. ( Ehmann, TS; Khanbhai, I; MacEwan, GW; Wrixon, C, 2001) |
| "Donepezil was safe and well-tolerated but was not effective compared with placebo as a cotreatment for the improvement of cognitive impairment in this patient population." | 6.73 | Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. ( Buchanan, RW; Goldman, R; Kane, JM; Keefe, RS; Li, C; Malhotra, AK; Meltzer, HY; Murthy, A; Sovel, M, 2008) |
| "Adjunctive treatment with donepezil improves cognition in patients with schizophrenia who are stabilized on atypical antipsychotics." | 5.14 | Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. ( Chung, YC; Kim, KW; Lee, CR; Park, TW; Yang, KH, 2009) |
| "Donepezil, 5 mg/d for 6 wk then 10 mg/d for 6 wk, and placebo daily for 12 wk in a double-blind cross-over paradigm, was added to the therapeutic regimen of 13 patients with schizophrenia or schizoaffective disorders, clinically stable on atypical antipsychotic medications." | 5.12 | Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2006) |
| "The article mentions the conclusions of most evidential works investigating donepezil in the treatment of cognitive deficit in schizophrenia." | 5.12 | Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study. ( Kadlecová, E; Lenderová, Z; Pérez, M; Pytela, O; Tůma, I; Zemanová, M, 2006) |
| "Donepezil does not seem to improve negative signs and cognitive impairment in elderly patients with chronic schizophrenia." | 5.12 | Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. ( Barak, Y; Mazeh, D; Mirecki, I; Paleacu, D; Zemishlani, H, 2006) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 5.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen." | 5.12 | Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2007) |
| "Similar to other studies using acetylcholinesterase inhibitors in more heterogeneous and symptomatic groups of patients with schizophrenia, donepezil does not appear to enhance cognitive abilities." | 5.12 | No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. ( Bilker, W; Gur, RC; Gur, RE; Kohler, CG; Kujawski, E; Martin, EA, 2007) |
| "Sixteen male patients with schizophrenia, who were receiving stable, physician-optimized risperidone (1-4 mg twice daily), and 15 healthy age- and weight-matched male controls, received donepezil HCl 5 mg daily for 7 days." | 5.11 | Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ( Cullen, EI; Khan, A; Kumar, D; Perdomo, CA; Pratt, RD; Preskorn, SH; Reyes, JF, 2004) |
| "Our aim was to examine if donepezil administered to stable, medicated outpatients with schizophrenia improves cognition and psychopathology." | 5.11 | Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. ( Cather, C; Deckersbach, T; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Herz, L, 2005) |
| "A pilot study was conducted to examine if donepezil could enhance cognitive function in patients with schizophrenia." | 5.10 | An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. ( Buchanan, RW; Gold, J; Summerfelt, A; Tek, C, 2003) |
| "The results of several clinical trials utilizing donepezil as an adjunct to second-generation antipsychotic drugs targeting cognitive deficits in schizophrenia subjects have been disappointing and would not lead clinicians to consider this as a potential treatment option." | 4.89 | Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia. ( Henderson, DC; Thakurathi, N; Vincenzi, B, 2013) |
| "This review discusses the laboratory and clinical research supporting the rationale for the efficacy of donepezil (Aricept USA) in enhancing cognition in autism, Alzheimer disease, Down syndrome, traumatic brain injury, Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia." | 4.84 | Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature. ( Valdovinos, MG; Williams, DC; Yoo, JH, 2007) |
| "Donepezil is the first-line of treatment for Alzheimer's disease (AD), which improves cognitive impairment effectively, but whether it has an impact on cognitive impairment in schizophrenia remains unknown." | 3.88 | The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia. ( Chen, T; He, L; Jia, XF; Li, YX; Ye, ZH, 2018) |
| "To assess the clinical and cognitive effects of adding donepezil, a reversible acetylcholinesterase inhibitor, to the risperidone treatment of a high functioning stable out-patient with schizophrenia." | 3.71 | Donepezil in schizophrenia--is it helpful? An experimental design case study. ( Ehmann, TS; Khanbhai, I; MacEwan, GW; Wrixon, C, 2001) |
| "Donepezil was safe and well-tolerated but was not effective compared with placebo as a cotreatment for the improvement of cognitive impairment in this patient population." | 2.73 | Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. ( Buchanan, RW; Goldman, R; Kane, JM; Keefe, RS; Li, C; Malhotra, AK; Meltzer, HY; Murthy, A; Sovel, M, 2008) |
| "The lifetime prevalence of visual hallucinations in patients with schizophrenia is much more common than conventionally thought and ranges from 24% to 72%." | 2.46 | Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature. ( Attard, A; Jacobsen, P; Patel, SS; Shergill, S, 2010) |
| "Donepezil does not cause liver toxicity or significant drug interactions and is relatively well-tolerated." | 2.42 | Donepezil: a clinical review of current and emerging indications. ( Rogers, SJ; Román, GC, 2004) |
| "Donepezil was able to fully reverse the effects of biperiden on N50 sensory gating, but had residual effects when combined with scopolamine; i." | 1.39 | Cholinergic gating of hippocampal auditory evoked potentials in freely moving rats. ( Blokland, A; Klinkenberg, I; Sambeth, A, 2013) |
| "Donepezil was added to their usual treatment for 8 weeks." | 1.33 | Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. ( Bergman, J; Brettholz, I; Dwolatzky, T; Lerner, V, 2005) |
| "Ten patients with schizophrenia or schizoaffective disorder who received stable doses of antipsychotics and met DSM-IV criteria for TD were treated with donepezil, 5 to 10 mg/day, for 6 weeks after a 2-week baseline period." | 1.31 | Treatment of tardive dyskinesia with donepezil: a pilot study. ( Campbell, EC; Caroff, SN; Gallop, R; Havey, J; Mann, SC; Sullivan, KA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (75.68) | 29.6817 |
| 2010's | 8 (21.62) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Juza, R | 1 |
| Vojtechova, I | 1 |
| Stefkova-Mazochova, K | 1 |
| Dehaen, W | 1 |
| Petrasek, T | 1 |
| Prchal, L | 1 |
| Kobrlova, T | 1 |
| Janousek, J | 1 |
| Vlcek, P | 1 |
| Mezeiova, E | 1 |
| Svozil, D | 1 |
| Karasova, JZ | 1 |
| Pejchal, J | 1 |
| Stark, H | 1 |
| Satala, G | 1 |
| Bojarski, AJ | 1 |
| Kubacka, M | 1 |
| Mogilski, S | 1 |
| Randakova, A | 1 |
| Musilek, K | 1 |
| Soukup, O | 1 |
| Korabecny, J | 1 |
| Li, YX | 1 |
| Ye, ZH | 1 |
| Chen, T | 1 |
| Jia, XF | 1 |
| He, L | 1 |
| Morozova, MA | 1 |
| Lepilkina, TA | 1 |
| Rupchev, GE | 1 |
| Beniashvily, AG | 1 |
| Burminskiy, DS | 1 |
| Potanin, SS | 1 |
| Bondarenko, EV | 1 |
| Kazey, VI | 1 |
| Lavrovsky, Y | 1 |
| Ivachtchenko, AV | 1 |
| Karamihalev, S | 1 |
| Prickaerts, J | 1 |
| van Goethem, NP | 1 |
| Akhondzadeh, S | 1 |
| Gerami, M | 1 |
| Noroozian, M | 1 |
| Karamghadiri, N | 1 |
| Ghoreishi, A | 1 |
| Abbasi, SH | 1 |
| Rezazadeh, SA | 1 |
| Rao, NP | 1 |
| Palaniyappan, P | 1 |
| Chandur, J | 1 |
| Venkatasubramanian, G | 1 |
| Gangadhar, BN | 1 |
| Chung, YC | 1 |
| Lee, CR | 1 |
| Park, TW | 1 |
| Yang, KH | 1 |
| Kim, KW | 1 |
| Patel, SS | 1 |
| Attard, A | 1 |
| Jacobsen, P | 1 |
| Shergill, S | 1 |
| Singh, J | 1 |
| Kour, K | 1 |
| Jayaram, MB | 1 |
| Cannon, CE | 1 |
| Puri, V | 1 |
| Vivian, JA | 1 |
| Egbertson, MS | 1 |
| Eddins, D | 1 |
| Uslaner, JM | 1 |
| Klinkenberg, I | 1 |
| Sambeth, A | 1 |
| Blokland, A | 1 |
| Thakurathi, N | 1 |
| Vincenzi, B | 1 |
| Henderson, DC | 2 |
| Howard, AK | 1 |
| Thornton, AE | 1 |
| Altman, S | 1 |
| Honer, WG | 1 |
| Buchanan, RW | 2 |
| Summerfelt, A | 1 |
| Tek, C | 1 |
| Gold, J | 1 |
| Hori, K | 1 |
| Oda, T | 1 |
| Tominaga, I | 1 |
| Inada, T | 1 |
| Nahas, Z | 3 |
| George, MS | 1 |
| Horner, MD | 3 |
| Markowitz, JS | 3 |
| Li, X | 1 |
| Lorberbaum, JP | 1 |
| Owens, SD | 1 |
| McGurk, S | 1 |
| DeVane, L | 1 |
| Risch, SC | 3 |
| Mazeh, D | 2 |
| Mirecki, I | 2 |
| Paleacu, D | 2 |
| Barak, Y | 2 |
| Román, GC | 1 |
| Rogers, SJ | 1 |
| Tuğal, O | 1 |
| Yazici, KM | 1 |
| Anil Yağcioğlu, AE | 1 |
| Göğüş, A | 1 |
| Stryjer, R | 2 |
| Strous, R | 1 |
| Bar, F | 2 |
| Shaked, G | 1 |
| Shiloh, R | 1 |
| Rozencwaig, S | 1 |
| Grupper, D | 1 |
| Buchman, N | 1 |
| Kotler, M | 1 |
| Rabey, JM | 2 |
| Weizman, A | 1 |
| Reyes, JF | 1 |
| Preskorn, SH | 1 |
| Khan, A | 1 |
| Kumar, D | 1 |
| Cullen, EI | 1 |
| Perdomo, CA | 1 |
| Pratt, RD | 1 |
| Bergman, J | 1 |
| Dwolatzky, T | 1 |
| Brettholz, I | 1 |
| Lerner, V | 1 |
| Freudenreich, O | 1 |
| Herz, L | 1 |
| Deckersbach, T | 1 |
| Evins, AE | 1 |
| Cather, C | 1 |
| Goff, DC | 1 |
| McGurk, SR | 2 |
| Palecko, S | 2 |
| DeVane, CL | 2 |
| Zemishlani, H | 1 |
| Pérez, M | 1 |
| Tůma, I | 1 |
| Pytela, O | 1 |
| Kadlecová, E | 1 |
| Zemanová, M | 1 |
| Lenderová, Z | 1 |
| Lee, BJ | 1 |
| Lee, JG | 1 |
| Kim, YH | 1 |
| Yoo, JH | 1 |
| Valdovinos, MG | 1 |
| Williams, DC | 1 |
| Keefe, RS | 1 |
| Malhotra, AK | 1 |
| Meltzer, HY | 1 |
| Kane, JM | 1 |
| Murthy, A | 1 |
| Sovel, M | 1 |
| Li, C | 1 |
| Goldman, R | 1 |
| Kohler, CG | 1 |
| Martin, EA | 1 |
| Kujawski, E | 1 |
| Bilker, W | 1 |
| Gur, RE | 1 |
| Gur, RC | 1 |
| Voss, B | 1 |
| Thienel, R | 1 |
| Leucht, S | 1 |
| Kircher, T | 1 |
| Caroff, SN | 2 |
| Campbell, EC | 2 |
| Havey, JC | 1 |
| Sullivan, KA | 2 |
| Katz, IR | 1 |
| Mann, SC | 2 |
| MacEwan, GW | 1 |
| Ehmann, TS | 1 |
| Khanbhai, I | 1 |
| Wrixon, C | 1 |
| Havey, J | 1 |
| Gallop, R | 1 |
| Friedman, JI | 1 |
| Adler, DN | 1 |
| Howanitz, E | 1 |
| Harvey, PD | 1 |
| Brenner, G | 1 |
| Temporini, H | 1 |
| White, L | 1 |
| Parrella, M | 1 |
| Davis, KL | 1 |
| Strous, RD | 1 |
| Baruch, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Tardive Dyskinesia With Galantamine[NCT00164242] | Phase 4 | 36 participants | Interventional | 2002-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for donepezil and Dementia Praecox
| Article | Year |
|---|---|
Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature.
Topics: Cholinesterase Inhibitors; Donepezil; Galantamine; Hallucinations; Humans; Indans; Phenylcarbamates; | 2010 |
Acetylcholinesterase inhibitors for schizophrenia.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarba | 2012 |
Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia.
Topics: Binding Sites; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; | 2013 |
Donepezil: a clinical review of current and emerging indications.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2004 |
Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.
Topics: Alzheimer Disease; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Autistic Disor | 2007 |
[Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans | 2008 |
17 trials available for donepezil and Dementia Praecox
| Article | Year |
|---|---|
Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.
Topics: Adult; Animals; Antipsychotic Agents; Attention; Behavior, Animal; Cholinergic Antagonists; Cholines | 2014 |
A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Donepezil; Double-Blind Method; Female; Humans; Indans | 2008 |
Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Donepezil; Dose-Response Relationship, Drug; Drug | 2009 |
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Donepezil; Drug Therapy, Combinat | 2003 |
Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Cross-Over Studies; Don | 2003 |
A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia.
Topics: Adult; Cognition Disorders; Cross-Over Studies; Donepezil; Double-Blind Method; Female; Humans; Inda | 2004 |
Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Cross-Over Studies; Donepezil; Do | 2004 |
Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Area Under Curve; Cholinesterase Inhibitors | 2004 |
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial.
Topics: Capsules; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Dose-Response Relationship, Dru | 2005 |
Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Affect; Analysis of Variance; Cross-Over Studies; Donepezil; Double-Blind Method; Female; Hum | 2006 |
Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Comorbidity; Cr | 2006 |
Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study.
Topics: Adolescent; Adult; Cholinesterase Inhibitors; Cognition Disorders; Czech Republic; Donepezil; Double | 2006 |
A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Chronic Disease; Cognition Disorders; Donepe | 2007 |
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Clozapine; Cross-Over Studi | 2007 |
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Double-B | 2008 |
No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia.
Topics: Adult; Brain; Brief Psychiatric Rating Scale; Cholinesterase Inhibitors; Cognition Disorders; Diagno | 2007 |
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Donepezil; Dose-Response Relationship, Drug; | 2002 |
14 other studies available for donepezil and Dementia Praecox
| Article | Year |
|---|---|
Novel D
Topics: Animals; Antipsychotic Agents; Piperazines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia | 2022 |
The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Donepezil; Excitatory Amino Acid Antagonists; M | 2018 |
Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia.
Topics: Acetylcholinesterase; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Aza Co | 2014 |
Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report.
Topics: Adult; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Electroconvulsive Therapy; Female; | 2009 |
The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Behavior, Animal; Benzylidene Compounds; Cholinest | 2013 |
Cholinergic gating of hippocampal auditory evoked potentials in freely moving rats.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Biperiden; Cholinergic Neurons; Cholinesterase Inhibit | 2013 |
Donepezil for memory dysfunction in schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Dibenzothiazepines; Donepezil; Drug Therapy, Combination; Fem | 2002 |
'Awakenings' in demented patients.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Awareness; Cholinesterase Inhibitors; Delusions; Depr | 2003 |
Donepezil for the treatment of a schizophrenia patient with frontal lobotomy.
Topics: Aged; Donepezil; Frontal Lobe; Humans; Indans; Male; Piperidines; Psychosurgery; Schizophrenia | 2003 |
Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Cholinesterase Inhibitors; Cog | 2005 |
Treatment of tardive dyskinesia with donepezil.
Topics: Adult; Aged; Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedul | 2001 |
Donepezil in schizophrenia--is it helpful? An experimental design case study.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition; Donepezil; Drug Therapy, Combinat | 2001 |
Treatment of tardive dyskinesia with donepezil: a pilot study.
Topics: Adult; Aged; Antipsychotic Agents; Donepezil; Dose-Response Relationship, Drug; Drug Administration | 2001 |
Donepezil management of schizophrenia with associated dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Comorbidity; Dementia; Donepezil; Drug Therapy, Co | 2002 |